KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Receivables - Net (2016 - 2025)

Historic Receivables - Net for West Pharmaceutical Services (WST) over the last 17 years, with Q4 2025 value amounting to $574.4 million.

  • West Pharmaceutical Services' Receivables - Net rose 396.38% to $574.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $574.4 million, marking a year-over-year increase of 396.38%. This contributed to the annual value of $574.4 million for FY2025, which is 396.38% up from last year.
  • As of Q4 2025, West Pharmaceutical Services' Receivables - Net stood at $574.4 million, which was up 396.38% from $625.0 million recorded in Q3 2025.
  • West Pharmaceutical Services' Receivables - Net's 5-year high stood at $625.0 million during Q3 2025, with a 5-year trough of $465.7 million in Q1 2021.
  • Over the past 5 years, West Pharmaceutical Services' median Receivables - Net value was $516.2 million (recorded in 2023), while the average stood at $520.8 million.
  • In the last 5 years, West Pharmaceutical Services' Receivables - Net surged by 4107.46% in 2021 and then tumbled by 1029.19% in 2024.
  • Quarter analysis of 5 years shows West Pharmaceutical Services' Receivables - Net stood at $489.0 million in 2021, then grew by 3.76% to $507.4 million in 2022, then rose by 0.91% to $512.0 million in 2023, then rose by 7.91% to $552.5 million in 2024, then grew by 3.96% to $574.4 million in 2025.
  • Its Receivables - Net stands at $574.4 million for Q4 2025, versus $625.0 million for Q3 2025 and $582.4 million for Q2 2025.